LIVIA CAROLINE MARIANO COMPTE
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- The impact of low dose busulfan on gonodal function after allogeneic hematopoietic stem cell transplantation for aplastic anemia(2020) KERBAUY, Mariana Nassif; MARIANO, Livia; SEBER, Adriana; ROCHA, Vanderson
conferenceObject BMT BRAZILIAN MAP: COMPARISON OF BMT MAP WITH EBMT ACTIVITY SURVEY AND ACTIVITY REPORT CIBMTR(2023) SIMIONE, Anderson Joao; SEBER, Adriana; MARIANO, Livia Caroline Barbosa; GERALDO, Bruna Leticia da Silva Santos; SANTOS, Rosana Machado dos; TALARICO, Wiliam Odair; VERGUEIRO, Carmen Silvia Vieitas- Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival(2023) VIGORITO, Afonso Celso; MIRANDA, Eliana Cristina Martins; COLTURATO, Vergilio Antonio Rensi; FUNKE, Vaneuza Araujo Moreira; FATOBENE, Giancarlo; MARIANO, Livia; MACEDO, Maria Cristina Martins de Almeida; RIBEIRO, Lorena Bedotti; DAUDT, Liane Esteves; MOREIRA, Maria Claudia Rodrigues; BONFIM, Carmem; COLELLA, Marcos Paulo; SEBER, Adriana; RODRIGUES, Morgani; DUARTE, Fernando Barroso; MARTIN, Paul J.; FLOWERS, Mary E. D.Failure-free survival (FFS), defined as the absence of new systemic treatment, recurrence of original malignancy and mortality not associated with recurrence after allogeneic hematopoietic stem cell transplantation (HCT), is a robust clinical measure to interpret results of initial systemic treatment of chronic graft-versus-host disease (cGVHD). We evaluate FFS after initial treatment of cGVHD in a mixed-race cohort from a resource-constrained country. This retrospective study included 354 consecutive patients after their first HCT between January 2014 and August 2020, who received initial systemic treatment for moderate or severe cGVHD at 13 Brazilian centers. Cox regression models were used to identify risk factors for treatment failure. The overall median follow-up among survivors was 28 months (range 1-71) after initial treatment. FFS was 89% at 6 months, 71% at 1 year and 52% at 2 years. New systemic treatment was the major cause of failure. In multivariable models, prior grades II-IV acute GVHD, a National Institutes of Health severity score of 3 in liver, gastrointestinal tract or lung involvement, and onset of initial treatment of cGVHD within 12 months after transplantation were all associated with an increased risk of treatment failure. Our results could serve as a benchmark for the design of future clinical trials evaluating initial treatment of cGVHD in resource-constrained locations.
conferenceObject EDUCATIONAL AUDIT PROCESS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) REPORTS(2023) GERALDO, Bruna; SIMIONE, Anderson; SEBER, Adriana; MARIANO, Livia; VERGUEIRO, CarmenconferenceObject Viral Reactivation after T-Cell Replete Haploidentical Transplantation Using Myeloablative Conditioning and Post-Transplant Cyclophosphamide(2016) BEZERRA, Evandro; SILVA, Roberto Luiz da; SCHMIDT FILHO, Jayr; SANTOS, Marina; NASCIMENTO, Marina; SIMOES, Aline; XAVIER, Erick; ALMEIDA, Manuella; MARIANO, Livia Caroline; FERNANDES, Pedro; MARQUES, Larissa; COSTA, Sylvia; SEBER, Adriana; MACEDO, Maria Cristina; MACHADO, ClarisseconferenceObject Fertility Outcomes after Allogeneic Hematopoietic Stem Cell Transplants Conditioned with Busulfan 4 Mg/Kg and Cyclophosphamide 200 Mg/Kg to Treat Severe Aplastic Anemia(2015) KERBAUY, Mariana Nassif; MARIANO, Livia Caroline Barbosa; MENEZES, Erick; DANTAS, Evandro; SOBRINHO, Jayr Schmidt; NASCIMENTO, Marina M.; SILVA, Roberto; MACEDO, Maria Cristina; GUALANDRO, Sandra; SEBER, Adriana